Happy Thanksgiving with the most impressive KM curve you’ll see today. PFS for first line nivo/ipi vs chemo in MSI-H mCRC. 🛻 Truck test: <0.001 nejm.org/doi/full/10.10…

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 Thanos Dimopoulos NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 OncoAlert

🔥🚨OncoAlert Hot off the press. U.S. FDA approves NEW #ALK inhibitor (#Ensartinib) for 1st line Tx of advanced #ALK+ #NSCLC Approval based on #eXALT3 trial of #Ensartinib vs #Crizotinib. ⬆️ #mPFS: 25.8 vs 12.7 months (HR: 0.56). No #OS difference 👇🏼 tinyurl.com/32d267b8

And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile. ⛹🏼‍♂️A new player for doublets in mHSPC! #ESMO24 Dr. Fred Saad silke gillessen

Let's learn hematology in 2025🩸 Day 34: thrombocytopenia in liver cirrhosis

❤️‍🩹 Cardiotoxicity of osimertinib is real. In this Korean study, osimertinib-related cardiotoxicity was 4.7%, including 3.4% requiring cardiologic intervention. Age and previous heart conditions identified. Implications for long-lasting treatment. #LCSM . jto.org/article/S1556-…

CEPHEUS out! 👏 Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 et al. PFS ⬆️ ⬆️ with quad in ø ASCT #MMsm. Nice discussion of similarities (many) & differences (few) vs IMROZ. 📢 CD38-VRd now the norm for many: time to shift algorithms to quad-eligible vs not regardless of ASCT plans! nature.com/articles/s4159…

Our 2025 #AMLsm updates is out! AmericanJournalofHematology. An up to date one stop-shop for diagnosis, risk stratificaion and managment, inlcuding new therapuetic algorithms. Free access to the full manuscript. onlinelibrary.wiley.com/doi/full/10.10… Richard Stone Dana-Farber

Breast cancer pearl of the day to my non-breast onc specialists out there: if your patient has a very medial tumor it’s important to get a breast MRI for staging because these often drain to the IM nodes and not the axillary. Knowing if IM nodes are + is important!. #OncTwitter

If you are anything like me, you might be feeling like picture one w the current HER2 landscape- feeling low and ultra low!! I created this HER2 definition table for my journal club and thought would share! hope this helps. 🤣 Medical Oncology Group of Australia (MOGA) Oncology Brothers OncoDaily OncoAlert OncLive.com

2025 prostate cancer staging from National Comprehensive Cancer Network (NCCN) and AJCC 8th edition Major change in 2025 NCCN vs prior years: Very high risk disease is now per STAMPEDE criteria (not Hopkins)

💥 Tarlatamab improves survival in 2nd line SCLC. DeLLphi-304 results demonstrated statistical significant and clinically meaningful improvement in overall survival compared to standard of care chemotherapy. #LCSM ⁦SmallCellSMASHERS⁩ investors.amgen.com/news-releases/…

Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… JCO Oncology Practice OncoAlert #JCOOP

Aspirin can prevent colon cancer? ALASCCA was a mic drop presentation at GI-ASCO earlier this year, but hasn't gotten the press it deserves. Pop: 1100 Resected colorectal cancer patients with PI3k mutation Intervention: 160mg Aspirin x 3 years Outcome: DFS HR .61 🤯, TTR .49

One page takeaway from #NIAGARA study that resulted in #durvalumab’s FDA Oncology approval on March 28, 2025 for resectable muscle invasive #BladderCancer #OncTwitter #MedTwitter #gusm OncoAlert Tom Powles

We released a 2 part update w/ our guest Jeff Auletta from NMDP & CIBMTR on SCT 🩸 (from our initial ep 9/25/23) 🧬 part 1: what is SCT, types & risks of SCT, how to find a donor, barriers/inequities 🧬 part 2: conditioning regimens, GvHD, toxicities & career path

Pembrolizumab now FDA Oncology approved in resectable LA-HNSCC based off KEYNOTE-689: - mEFS: 51.8 vs 30.4 most (HR: 0.73) - Benefit greater with CPS ≥10 (HR 0.66) - 2yr EFS: 75% vs 62% #OncTwitter #MedTwitter OncoAlert #ASCO25 #AACR25

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

Treatment Algorithm: This is the algorithm we have used during our discussion w/ Deepa Rangachari, MD, FASCO for Stage I-III non-small cell #LungCancer #OncTwitter #MedTwitter #lcsm